The aim of the study is to determine whether serum inflammatory angiogenic markers (eg, semaphorins, CCN1) predict severity of juvenile idiopathic arthritis defined by structural progression and/or therapeutic escalation.
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of chronic inflammatory rheumatic diseases beginning before the age of 16. The most common pediatric rheumatologic disease. JIA is the most common pediatric rheumatologic disease. Apart from clinical features and the biological inflammatory syndrome, no predictive parameter for the severity of JIA, especially polyarticular JIA, has been identified. The team has been interested in the prognosis of RA for many years. Thus, the investigators have conducted various studies in search of biological parameters associated with the joint prognosis of RA patients, which allowed the investigator to discover the interest of angiogenic and inflammatory biomarkers such as semaphorins and CCN1 protein. This has been demonstrated in vitro but also in vivo from sera of RA patients. These markers are associated with activity and structural damage in RA. The project aims to study the interest of these same angiogenic biomarkers in the serum of JIA patients in order to establish whether, as in RA, they are also associated with disease severity.
Study Type
OBSERVATIONAL
Enrollment
300
Addtional tube of blood needed for follow up of patients
Joint puncture if needed according to routine care of the patients
Rheumatology Department, Cochin Hospital
Paris, IDF, France
RECRUITINGDosage of angiogenic markers
Dosage of angiogenic markers by ELISA method in serum. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.
Time frame: 5 years
Dosage of angiogenic markers
Dosage of angiogenic markers by ELISA method in synovial fluid if available. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.
Time frame: 5 years
Dosage of inflammatory markers by ELISA method
Dosage of inflammatory markers by ELISA method in serum. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.
Time frame: 5 years
Dosage of inflammatory markers by ELISA method
Dosage of inflammatory markers by ELISA method in synovial fluid if available. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.
Time frame: 5 years
Questionnaires
Severity of JIA
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Collection of treatments received
Severity of JIA
Time frame: 5 years
Structural damage determined by x-rays
Structural damage determined by x-rays during follow up.
Time frame: 5 years
Angiogenic biomarkers
Determine if sera angiogenic biomarkers are associated with clinical subtypes of JIA.
Time frame: At inclusion
Inflammatory biomarkers
Determine if sera inflammatory biomarkers are associated with clinical subtypes of JIA.
Time frame: At inclusion